News

Net Loss of Virinchi reported to Rs 14.61 crore in the quarter ended March 2026 as against net loss of Rs 4.38 crore during the previous quarter ended March 2025. Sales declined 4.31% to Rs 65.97 crore in the quarter ended March 2026 as against Rs 68.94 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 26.12 crore in the year ended March 2026 as against net profit of Rs 0.72 crore during the previous year ended March 2025. Sales declined 5.57% to Rs 284.36 crore in the year ended March 2026 as against Rs 301.13 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales65.9768.94 -4 284.36301.13 -6 OPM %3.2424.35 -22.6629.63 - PBDT-4.4612.79 PL 33.2957.36 -42 PBT-18.34-1.13 -1523 -22.932.37 PL NP-14.61-4.38 -234 -26.120.72 PL Powered by Capital Market - Live News

Virinchi will hold a meeting of the Board of Directors of the Company on 28 May 2026.

Net profit of Virinchi declined 55.97% to Rs 1.66 crore in the quarter ended December 2025 as against Rs 3.77 crore during the previous quarter ended December 2024. Sales declined 6.69% to Rs 76.89 crore in the quarter ended December 2025 as against Rs 82.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales76.8982.40 -7 OPM %33.3632.37 - PBDT18.1317.40 4 PBT4.111.73 138 NP1.663.77 -56 Powered by Capital Market - Live News

Virinchi will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live News

Virinchi has allotted 74,00,000 convertible equity warrants at an issue price of Rs 28 (face value of Rs 10 and premium of Rs 18) per share on preferential basis to promoter group entity, Vivo Bio Tech on 09 January 2026. Powered by Capital Market - Live News